Status:
COMPLETED
PVP-I Nasal Sprays and SARS-CoV-2 Nasopharyngeal Titers (for COVID-19)
Lead Sponsor:
Stanford University
Conditions:
COVID-19
Eligibility:
All Genders
18+ years
Phase:
PHASE1
PHASE2
Brief Summary
The study aims to determine the safety and efficacy of povidone-iodine (PVP-I) containing nasal sprays as compared to isotonic saline nasal sprays in COVID-19 positive patients. The primary outcome me...
Eligibility Criteria
Inclusion
- Diagnosis of COVID-19 by lab test within 5 days of study participation
Exclusion
- Allergy to "iodine," shellfish, or food dye
- Receiving intranasal steroids
- Sinus surgery within 30 days of beginning the study
- Intubated at the time of enrollment
- Pregnancy
- Participation in other COVID-19 studies - to be determined on a case by case basis
Key Trial Info
Start Date :
August 15 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 13 2020
Estimated Enrollment :
47 Patients enrolled
Trial Details
Trial ID
NCT04347954
Start Date
August 15 2020
End Date
December 13 2020
Last Update
October 21 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Stanford Health Care
Stanford, California, United States, 94305